Acadia Pharmaceuticals Inc (ACAD) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and the potential opportunities and threats. The profile helps you formulate strategies that augment your business by enabling you to understand your partners, customers and competitors better.
The profile contains critical company information including:
- Business description – A detailed description of the company’s operations and business divisions.
- Corporate strategy – Analyst’s summarization of the company’s business strategy.
- SWOT Analysis – A detailed analysis of the company’s strengths, weakness, opportunities and threats.
- Company history – Progression of key events associated with the company.
- Major products and services – A list of major products, services and brands of the company.
- Key competitors – A list of key competitors to the company.
- Key employees – A list of the key executives of the company.
- Executive biographies – A brief summary of the executives’ employment history.
- Key operational heads – A list of personnel heading key departments/functions.
- Important locations and subsidiaries – A list and contact details of key locations and subsidiaries of the company.
- Key manufacturing facilities – A list of key manufacturing facilities of the company.
- Detailed financial ratios for the past five years – The latest financial ratios derived from the annual financial statements published by the company with 5 years history.
- Interim ratios for the last five interim periods – The latest financial ratios derived from the quarterly/semi-annual financial statements published by the company for 5 interims history.
Highlights
Acadia Pharmaceuticals Inc (Acadia) discovers, develops and commercializes small molecule drugs for the treatment of central nervous system disorders. Acadia’s lead product Nuplazid (pimavanserin) is a FDA approved drug for the treatment of Parkinson’s disease psychosis. Its other pipeline products include pimavanserin for the treatment of Alzheimer’s disease agitation, Alzheimer’s disease psychosis, schizophrenia inadequate response, schizophrenia negative symptoms and major depressive disorder. The company has partnerships with Allergen for the development of its drug candidates in the therapeutic areas of pain and ophthalmology. It has its operational presence with offices located in Denmark and Switzerland. Acadia is headquartered in San Diego, California, the US.
Acadia Pharmaceuticals Inc Key Recent Developments
Mar 30,2017: ACADIA Pharmaceuticals Announces Appointment of Michael J. Yang as Executive Vice President, Chief Commercial Officer
Feb 28,2017: ACADIA Pharmaceuticals Reports Financial Results for the Fourth Quarter and Year Ended December 31, 2016
Nov 07,2016: ACADIA Pharmaceuticals Reports Third Quarter 2016 Financial Results
Aug 24,2016: ACADIA Pharmaceuticals Announces Appointment of Todd S. Young as Executive Vice President, Chief Financial Officer
Aug 04,2016: ACADIA Pharmaceuticals Reports Second Quarter 2016 Financial Results
Key benefits of buying this profile include:
You get detailed information about the company and its operations to identify potential customers and suppliers.
- The profile analyzes the company’s business structure, operations, major products and services, prospects, locations and subsidiaries, key executives and their biographies and key competitors.
Understand and respond to your competitors’ business structure and strategies, and capitalize on their weaknesses. Stay up to date on the major developments affecting the company.
- The company’s core strengths and weaknesses and areas of development or decline are analyzed and presented in the profile objectively. Recent developments in the company covered in the profile help you track important events.
Equip yourself with information that enables you to sharpen your strategies and transform your operations profitably.
- Opportunities that the company can explore and exploit are sized up and its growth potential assessed in the profile. Competitive and/or technological threats are highlighted.
Scout for potential investments and acquisition targets, with detailed insight into the companies’ strategic, financial and operational performance.
- Financial ratio presented for major public companies in the profile include the revenue trends, profitability, growth, margins and returns, liquidity and leverage, financial position and efficiency ratios.
Gain key insights into the company for academic or business research.
- Key elements such as SWOT analysis, corporate strategy and financial ratios and charts are incorporated in the profile to assist your academic or business research needs.
Note: Some sections may be missing if data is unavailable for the company
Table of Contents
Table of Contents 3
List of Tables 5
List of Figures 5
Section 1 - About the Company 6
Acadia Pharmaceuticals Inc - Key Facts 6
Acadia Pharmaceuticals Inc - Key Employees 7
Acadia Pharmaceuticals Inc - Key Employee Biographies 8
Acadia Pharmaceuticals Inc - Major Products and Services 9
Acadia Pharmaceuticals Inc - Pharmaceutical Pipeline Products Data 10
Acadia Pharmaceuticals Inc, Pipeline Products by Therapy Area 10
Acadia Pharmaceuticals Inc, Pipeline Products by Development Phase 10
Acadia Pharmaceuticals Inc - History 12
Acadia Pharmaceuticals Inc - Company Statement 14
Acadia Pharmaceuticals Inc - Locations And Subsidiaries 17
Head Office 17
Other Locations & Subsidiaries 17
Section 2 – Company Analysis 18
Acadia Pharmaceuticals Inc - Business Description 18
Acadia Pharmaceuticals Inc - Corporate Strategy 19
Acadia Pharmaceuticals Inc - SWOT Analysis 20
SWOT Analysis - Overview 20
Acadia Pharmaceuticals Inc - Strengths 20
Acadia Pharmaceuticals Inc - Weaknesses 21
Acadia Pharmaceuticals Inc - Opportunities 22
Acadia Pharmaceuticals Inc - Threats 23
Acadia Pharmaceuticals Inc - Key Competitors 24
Section 3 – Company Financial Ratios 25
Financial Ratios - Capital Market Ratios 25
Financial Ratios - Annual Ratios 26
Performance Chart 28
Financial Performance 28
Financial Ratios - Interim Ratios 29
Financial Ratios - Ratio Charts 30
Section 4 – Company’s Lifesciences Financial Deals and Alliances 31
Acadia Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017 31
Acadia Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Type, 2011 to YTD 2017 32
Acadia Pharmaceuticals Inc, Recent Deals Summary 33
Section 5 – Company’s Recent Developments 34
Mar 30, 2017: ACADIA Pharmaceuticals Announces Appointment of Michael J. Yang as Executive Vice President, Chief Commercial Officer 34
Feb 28, 2017: ACADIA Pharmaceuticals Reports Financial Results for the Fourth Quarter and Year Ended December 31, 2016 35
Nov 07, 2016: ACADIA Pharmaceuticals Reports Third Quarter 2016 Financial Results 37
Aug 24, 2016: ACADIA Pharmaceuticals Announces Appointment of Todd S. Young as Executive Vice President, Chief Financial Officer 39
Aug 04, 2016: ACADIA Pharmaceuticals Reports Second Quarter 2016 Financial Results 40
May 05, 2016: ACADIA Pharmaceuticals Reports First Quarter 2016 Financial Results 42
Feb 29, 2016: ACADIA Pharmaceuticals Reports Financial Results for the Fourth Quarter and Year Ended December 31, 2015 43
Jan 25, 2016: ACADIA Pharmaceuticals Appoints James R. Owen, M.D., as Senior Vice President, Clinical Development and Chief Medical Officer 44
Jan 11, 2016: ACADIA Pharmaceuticals Appoints Jim Daly to Board of Directors 45
Section 6 – Appendix 46
Methodology 46
Ratio Definitions 46
About GlobalData 50
Contact Us 50
Disclaimer 50List of Tables
Acadia Pharmaceuticals Inc, Key Facts 6
Acadia Pharmaceuticals Inc, Key Employees 7
Acadia Pharmaceuticals Inc, Key Employee Biographies 8
Acadia Pharmaceuticals Inc, Major Products and Services 9
Acadia Pharmaceuticals Inc, Number of Pipeline Products by Development Stage 11
Acadia Pharmaceuticals Inc, History 12
Acadia Pharmaceuticals Inc, Subsidiaries 17
Acadia Pharmaceuticals Inc, Key Competitors 24
Acadia Pharmaceuticals Inc, Ratios based on current share price 25
Acadia Pharmaceuticals Inc, Annual Ratios 26
Acadia Pharmaceuticals Inc, Annual Ratios (Cont...1) 27
Acadia Pharmaceuticals Inc, Interim Ratios 29
Acadia Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017 31
Acadia Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Type, 2011 to YTD 2017 32
Acadia Pharmaceuticals Inc, Recent Deals Summary 33
Currency Codes 46
Capital Market Ratios 46
Equity Ratios 47
Profitability Ratios 47
Cost Ratios 48
Liquidity Ratios 48
Leverage Ratios 49
Efficiency Ratios 49List of Figures
Acadia Pharmaceuticals Inc, Pipeline Products by Therapy Area 10
Acadia Pharmaceuticals Inc, Pipeline Products by Development Phase 10
Acadia Pharmaceuticals Inc, Performance Chart (2012 - 2016) 28
Acadia Pharmaceuticals Inc, Ratio Charts 30
Acadia Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017 31
Acadia Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals by Type, 2011 to YTD 2017 32
Sunovion Pharmaceuticals Inc
Pfizer Inc
Otsuka Pharmaceutical Co Ltd
Forest Laboratories LLC
Eisai Inc
